{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.72","upperLimit":"36.80","value":"34.66"},{"groupId":"OG001","lowerLimit":"28.65","upperLimit":"33.28","value":"30.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"546"},{"groupId":"OG001","value":"542"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1000 milligram (mg) abiraterone acetate tablets (as 4\\*250 mg tablets) orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG000","title":"Abiraterone Acetate + Prednisone (AAP)"},{"description":"Participants received placebo matched to abiraterone acetate tablets orally once daily along with prednisone 5 mg tablet orally twice daily, from Day 1, Cycle1 (each cycle consist of 28 days) up to radiographic progression of disease and/or unequivocal clinical progression.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat (ITT) population included all the randomized participants who were classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From randomization (Day 1) up to end of study (Month 60)","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"Months"}